Ovarian Cancer Drug Misses Mark… Right?

October 1, 2019 5:00 pm

By Charles Bankhead

Anti-folate fails phase III test, but key biomarker measurement may have been faulty.

An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more

Avelumab Combo Falls Short in Advanced Ovarian Cancer

March 20, 2019 7:00 pm

By Ian Ingram

But showed promise in PD-L1-positive group.

Adding avelumab (Bavencio) to pegylated liposomal doxorubicin (PLD) failed to improve survival outcomes for patients with platinum-resistant or refractory ovarian cancer in a phase III trial reported here.

In the intent-to-treat … Read more

SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer

March 19, 2019 3:00 pm

By Christina Bennett, MS

Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide showed clinical activity in patients with recurrent epithelial ovarian cancer, according to the results of an open-label phase II trial (LBA4) presented at the 2019 Society of … Read more

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18, 2019 3:30 pm

By Kristie L. Kahl

Lenvatinib (Lenvima) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate (ORR), according to results from a phase I study presented … Read more

ImmunoGen’s Ovarian Cancer Drug Misses Phase III Primary Endpoint

March 4, 2019 5:00 pm

US-based biotechnology company ImmunoGen has reported negative top-line results from the Phase III FORWARD I ovarian cancer trial of mirvetuximab soravtansine.

The study failed to meet its primary endpoint of progression-free survival (PFS). Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) … Read more

Tumor Treating Fields Plus Paclitaxel Appears Safe, Effective in Recurrent Ovarian Cancer

August 16, 2018 12:57 am
BY Kristie L. Kahl
The combination use of Tumor Treating Fields (TTFields) and paclitaxel more than doubled progression-free survival (PFS) in patients with recurrent, platinum-resistant ovarian cancer compared with those who received weekly paclitaxel, according to results from the phase … Read more

Non-Chemo Combo Active in Ovarian Cancer

June 6, 2018 7:00 pm

The combination of two targeted agents – the PARP inhibitor niraparib (Zejula) plus the checkpoint inhibitor pembrolizumab (Keytruda) — appears to elicit a durable response among women with heavily pretreated, refractory ovarian cancer, researchers reported here.

About 25% of women … Read more

SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer

April 2, 2018 5:19 pm

A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more